Establishing the standards in biomarker research

Thomson Reuters believes that biomarkers will become one of the major driving forces of pharmaceutical research and drug development in the coming years.

However, we recognise that research organisations face a number of hurdles in realizing these benefits due to the lack of trustworthy biomarkers data and standards in the public domain.

By drawing on the experience and knowledge of scientists in Prous Science, a Thomson Reuters business, as well as extensive participation by key stakeholders, Thomson Reuters is uniquely placed to establish and develop these standards, and to provide trusted, authoritative biomarker information.

To find out more information on the Thomson Reuters Biomarker offering and to receive a complementary copy of our white paper, Establishing the Standards in Biomarker Research, please complete the form below.

*Indicates required field

Pharma Matters White Paper from Thomson Reuters - Establishing the standards in biomarkers research

In this white paper, Thomson Reuters shows how the pharmaceutical industry is already beginning to rely on this information, and explains how important it is to establish the standards that will support increasing biomarker implementation in the future.

Thomson Reuters would like to keep you up to date with developments to our products and services. We would also like to invite you to special events such as seminars and receptions, and we would like you to benefit from our free newsletters and other resources.

Find out more about Thomson Reuters brands.

For information about our privacy policies or to change your communications preferences, please refer to our Privacy Statement.